Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

Quince Therapeutics (QNCX) “announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application ...

SOUTH SAN FRANCISCO, Calif. - Quince Therapeutics, Inc. (NASDAQ: QNCX), a biotech firm focusing on rare diseases with a current market capitalization of $67.76 million, has received a Notice of ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

The Schmitt family is grateful for the resources through A-T Children’s Project, as well as the love and care at St. Jude’s, ...

The event brought together 300 researchers, clinicians, industry leaders, and entrepreneurs to highlight their work.

and four (ataxia-telangiectasia, ataxia-telangiectasia-like disorder, Nijmegen breakage syndrome and Alzheimer's disease) exhibit defects in genes involved in repairing double-strand breaks.